Login to Your Account

Clinic Roundup

Thursday, October 31, 2013
• Spectrum Pharmaceuticals Inc., of Henderson, Nev., said it completed enrollment in a pivotal study of Captisol-enabled propylene glycol-free high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription